Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT-LAPSE OF IMPLEMENTATION PERIOD OF THE SHAREHOLDING INCREASE PLAN（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to it accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

LAPSE OF IMPLEMENTATION PERIOD OF THE

SHAREHOLDING INCREASE PLAN

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上海復星醫藥(集團)股份有限公司 (the ''Company'').

Reference is made to the announcements of the Company dated 30 December 2016, 19 January, 4 May and 23 May 2017 (the ''Announcements'') in relation to the Shareholding Increase Plan and its implementation by Mr. Wu Yifang (''Mr. Wu''), an executive director, president and chief executive officer of the Company. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Announcements.

THE SHAREHOLDING INCREASE PLAN

The period of the implementation of the Shareholding Increase Plan lapsed on 2 January 2018 (after trading hours). From 3 January 2017 to 2 January 2018 (both days inclusive), Mr. Wu, via the trading system of Shanghai Stock Exchange (including the Shanghai-Hong Kong Stock Connect) acquired an aggregate number of 755,900 Shares (including 443,900 A Shares and 312,000 H Shares) for an aggregate amount of approximately RMB20.90 million based on the middle exchange rates for Renminbi to Hong Kong dollars as announced by the People's Bank of China as at the date of the respective date of shareholding increase.

As at 2 January 2018 (after trading hours), Mr. Wu holds 995,900 Shares (including 683,900 A Shares and 312,000 H Shares), representing approximately 0.04% of the total issued shares of the Company (i.e. 2,495,131,045 Shares) as at the date of this announcement.

The Shareholding Increase Plan complied with the provisions of the Securities Law of the People's Republic of China and other applicable laws, regulations, department regulations and the relevant rules of Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

2 January 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can, and the independent non-executive directors of the Company are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

*

for identification purposes only